Candriam S.C.A. Sells 10,906 Shares of Neurocrine Biosciences, Inc. $NBIX

Candriam S.C.A. trimmed its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 3.7% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 287,645 shares of the company’s stock after selling 10,906 shares during the quarter. Candriam S.C.A. owned 0.29% of Neurocrine Biosciences worth $40,380,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Royal Bank of Canada increased its holdings in shares of Neurocrine Biosciences by 36.7% in the first quarter. Royal Bank of Canada now owns 82,810 shares of the company’s stock worth $9,158,000 after buying an additional 22,224 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Neurocrine Biosciences by 60.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,783 shares of the company’s stock valued at $1,647,000 after acquiring an additional 5,577 shares during the period. NewEdge Advisors LLC grew its position in Neurocrine Biosciences by 56.3% during the 1st quarter. NewEdge Advisors LLC now owns 7,630 shares of the company’s stock worth $844,000 after acquiring an additional 2,747 shares during the last quarter. Empowered Funds LLC purchased a new position in Neurocrine Biosciences in the 1st quarter worth approximately $1,333,000. Finally, Geneos Wealth Management Inc. increased its stake in Neurocrine Biosciences by 143.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after purchasing an additional 135 shares during the period. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on NBIX. Truist Financial dropped their price objective on Neurocrine Biosciences from $172.00 to $169.00 and set a “buy” rating for the company in a research note on Thursday, January 8th. Royal Bank Of Canada upped their price target on shares of Neurocrine Biosciences from $160.00 to $180.00 and gave the company an “outperform” rating in a report on Monday, December 8th. UBS Group cut their price target on shares of Neurocrine Biosciences from $188.00 to $178.00 and set a “buy” rating on the stock in a report on Friday, January 23rd. Needham & Company LLC boosted their price objective on shares of Neurocrine Biosciences from $170.00 to $184.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Finally, TD Cowen increased their target price on shares of Neurocrine Biosciences from $175.00 to $200.00 and gave the stock a “buy” rating in a report on Friday, December 5th. Fifteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $174.00.

Insider Buying and Selling

In other news, Director Leslie V. Norwalk sold 5,000 shares of Neurocrine Biosciences stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $152.23, for a total value of $761,150.00. Following the completion of the transaction, the director owned 7,429 shares of the company’s stock, valued at $1,130,916.67. The trade was a 40.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Darin Lippoldt sold 4,376 shares of the company’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $159.65, for a total transaction of $698,628.40. Following the completion of the transaction, the insider owned 43,405 shares in the company, valued at approximately $6,929,608.25. The trade was a 9.16% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 61,966 shares of company stock worth $8,625,166 over the last three months. 4.30% of the stock is owned by corporate insiders.

Neurocrine Biosciences Price Performance

Shares of NASDAQ NBIX opened at $141.20 on Monday. Neurocrine Biosciences, Inc. has a 1 year low of $84.23 and a 1 year high of $160.18. The stock has a market capitalization of $14.08 billion, a P/E ratio of 33.78, a P/E/G ratio of 0.66 and a beta of 0.31. The company’s 50-day moving average is $142.20 and its 200 day moving average is $140.51.

Neurocrine Biosciences Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.